1.Clinical and Intestinal Ultrasound Findings in Mitochondrial Neurogastrointestinal Encephalomyopathy:Report of One Case.
Xiao-Yan ZHANG ; Qing-Li ZHU ; Ge-Chong RUAN ; Wen-Bo LI
Acta Academiae Medicinae Sinicae 2025;47(5):758-761
Mitochondrial neurogastrointestinal encephalomyopathy(MNGIE),a rare mitochondrial disorder caused by TYMP gene mutations,is characterized by severe gastrointestinal dysmotility,peripheral neuropathy,and leukodystrophy.This article summarizes the clinical data and intestinal ultrasound findings of a MNGIE case,aiming to provide insights for clinical diagnosis and treatment.
Humans
;
Mitochondrial Encephalomyopathies/diagnostic imaging*
;
Ultrasonography
;
Intestines/diagnostic imaging*
;
Male
;
Female
;
Intestinal Pseudo-Obstruction/diagnostic imaging*
;
Ophthalmoplegia/congenital*
;
Muscular Dystrophy, Oculopharyngeal
2.A case of bromadiolone poisoning leading to digestive tract, abdominal hemorrhage and secondary paralytic ileus.
Hong Fan CHEN ; Zhi Jian ZHANG ; Cheng Jin YOU ; Li CHEN
Chinese Journal of Industrial Hygiene and Occupational Diseases 2022;40(9):707-709
Bromadiolone, commonly known as super warfarin, is a long-acting coumarin dicoumarin rodenticide. The mechanism of bromadiolone is mainly to inhibit vitamin K1 epoxide reductase and affect the synthesis of coagulation factors Ⅱ, Ⅶ, Ⅸ and Ⅹ, which causes blood coagulation dysfunction and systemic multiple organ hemorrhage. Here, we report of a case of bromadiolone poisoning patient who had digestive tract, abdominal hemorrhage, as well as secondary paralytic ileus. After blood product transfusion and vitamin K1 supplementation, the patient was discharged after the physical condition was improved. It's suggestied that clinicians should pay attention to rare complications to prevent missed diagnosis when treating other bromadiolone poisoning.
4-Hydroxycoumarins
;
Blood Coagulation Factors
;
Dicumarol
;
Hemorrhage
;
Humans
;
Intestinal Pseudo-Obstruction/chemically induced*
;
Oxidoreductases
;
Rodenticides
;
Vitamin K 1
;
Warfarin
3.Short Bowel Syndrome as the Leading Cause of Intestinal Failure in Early Life: Some Insights into the Management
Olivier GOULET ; Elie ABI NADER ; Bénédicte PIGNEUR ; Cécile LAMBE
Pediatric Gastroenterology, Hepatology & Nutrition 2019;22(4):303-329
Intestinal failure (IF) is the critical reduction of the gut mass or its function below the minimum needed to absorb nutrients and fluids required for adequate growth in children. Severe IF requires parenteral nutrition (PN). Pediatric IF is most commonly due to congenital or neonatal intestinal diseases or malformations divided into 3 groups: 1) reduced intestinal length and consequently reduced absorptive surface, such as in short bowel syndrome (SBS) or extensive aganglionosis; 2) abnormal development of the intestinal mucosa such as congenital diseases of enterocyte development; 3) extensive motility dysfunction such as chronic intestinal pseudo-obstruction syndromes. The leading cause of IF in childhood is the SBS. In clinical practice the degree of IF may be indirectly measured by the level of PN required for normal or catch up growth. Other indicators such as serum citrulline have not proven to be highly reliable prognostic factors in children. The last decades have allowed the development of highly sophisticated nutrient solutions consisting of optimal combinations of macronutrients and micronutrients as well as guidelines, promoting PN as a safe and efficient feeding technique. However, IF that requires long-term PN may be associated with various complications including infections, growth failure, metabolic disorders, and bone disease. IF Associated Liver Disease may be a limiting factor. However, changes in the global management of IF pediatric patients, especially since the setup of intestinal rehabilitation centres did change the prognosis thus limiting “nutritional failure” which is considered as a major indication for intestinal transplantation (ITx) or combined liver-ITx.
Bone Diseases
;
Child
;
Citrulline
;
Enterocytes
;
Humans
;
Intestinal Diseases
;
Intestinal Mucosa
;
Intestinal Pseudo-Obstruction
;
Liver Diseases
;
Micronutrients
;
Parenteral Nutrition
;
Parenteral Nutrition, Home
;
Prognosis
;
Rehabilitation
;
Short Bowel Syndrome
4.Waardenburg Syndrome Type IV De Novo SOX10 Variant Causing Chronic Intestinal Pseudo-Obstruction
Anthony R HOGAN ; Krishnamurti A RAO ; Willa L THORSON ; Holly L NEVILLE ; Juan E SOLA ; Eduardo A PEREZ
Pediatric Gastroenterology, Hepatology & Nutrition 2019;22(5):487-492
Waardenburg syndrome (WS) type IV is characterized by pigmentary abnormalities, deafness and Hirschsprung's disease. This syndrome can be triggered by dysregulation of the SOX10 gene, which belongs to the SOX (SRY-related high-mobility group-box) family of genes. We discuss the first known case of a SOX10 frameshift mutation variant defined as c.895delC causing WS type IV without Hirschsprung's disease. This female patient of unrelated Kuwaiti parents, who tested negative for cystic fibrosis and Hirschsprung's disease, was born with meconium ileus and malrotation and had multiple surgical complications likely due to chronic intestinal pseudo-obstruction. These complications included small intestinal necrosis requiring resection, development of a spontaneous fistula between the duodenum and jejunum after being left in discontinuity, and short gut syndrome. This case and previously reported cases demonstrate that SOX10 gene sequencing is a consideration in WS patients without aganglionosis but with intestinal dysfunction.
Cystic Fibrosis
;
Deafness
;
Duodenum
;
Female
;
Fistula
;
Frameshift Mutation
;
Hirschsprung Disease
;
Humans
;
Ileus
;
Intestinal Pseudo-Obstruction
;
Jejunum
;
Meconium
;
Necrosis
;
Parents
;
Waardenburg Syndrome
5.Colonic Pseudo-obstruction With Transition Zone: A Peculiar Eastern Severe Dysmotility
Eun Mi SONG ; Jong Wook KIM ; Sun Ho LEE ; Kiju CHANG ; Sung Wook HWANG ; Sang Hyoung PARK ; Dong Hoon YANG ; Kee Wook JUNG ; Byong Duk YE ; Jeong Sik BYEON ; Suk Kyun YANG ; Hyo Jeong LEE ; Chang Sik YU ; Chan Wook KIM ; Seong Ho PARK ; Jihun KIM ; Seung Jae MYUNG
Journal of Neurogastroenterology and Motility 2019;25(1):137-147
BACKGROUND/AIMS: Previous studies from Korea have described chronic intestinal pseudo-obstruction (CIPO) patients with transition zone (TZ) in the colon. In this study, we evaluated the pathological characteristics and their association with long-term outcomes in Korean colonic pseudo-obstruction (CPO) patients with TZ. METHODS: We enrolled 39 CPO patients who were refractory to medical treatment and underwent colectomy between November 1989 and April 2016 (median age at symptoms onset: 45 [interquartile range, 29–57] years, males 46.2%). The TZ was defined as a colonic segment connecting a proximally dilated and distally non-dilated segment. Detailed pathologic analysis was performed. RESULTS: Among the 39 patients, 37 (94.9%) presented with TZ and 2 (5.1%) showed no definitive TZ. Median ganglion cell density in the TZ adjusted for the colonic circumference was significantly decreased compared to that in proximal dilated and distal non-dilated segments in TZ (+) patients (9.2 vs 254.3 and 150.5, P < 0.001). Among the TZ (+) patients, 6 showed additional pathologic findings including eosinophilic ganglionitis (n = 2), ulcers with combined cytomegalovirus infection (n = 2), diffuse ischemic changes (n = 1), and heterotropic myenteric plexus (n = 1). During follow-up (median, 61 months), 32 (82.1%) TZ (+) patients recovered without symptom recurrence after surgery. The presence of pathological features other than hypoganglionosis was an independent predictor of symptom recurrence after surgery (P = 0.046). CONCLUSIONS: Hypoganglionosis can be identified in the TZ of most Korean CPO patients. Detection of other pathological features in addition to TZ-associated hypoganglionosis was associated with poor post-operative outcomes.
Cell Count
;
Colectomy
;
Colon
;
Colonic Pseudo-Obstruction
;
Cytomegalovirus Infections
;
Eosinophils
;
Follow-Up Studies
;
Ganglion Cysts
;
Humans
;
Intestinal Pseudo-Obstruction
;
Korea
;
Male
;
Myenteric Plexus
;
Pathology
;
Recurrence
;
Ulcer
6.Ogilvie's Syndrome after Lumbar Spinal Surgery
Su Keon LEE ; Seung Hwan LEE ; Byeong Mun PARK ; Bong Seok YANG ; Ji Hyeon KIM ; Hwan Mo LEE
Journal of Korean Society of Spine Surgery 2019;26(2):63-67
STUDY DESIGN: Case report. OBJECTIVES: We report a case of Ogilvie's syndrome following posterior decompression surgery in a spinal stenosis patient who presented with acute abdominal distension, nausea, and vomiting. SUMMARY OF LITERATURE REVIEW: Ogilvie's syndrome is a rare and potentially fatal disease that can easily be mistaken for postoperative ileus, and is also known as acute colonic pseudo-obstruction. Early recognition and diagnosis enable treatment prior to bowel perforation and requisite abdominal surgery. MATERIALS AND METHODS: An 82-year-old woman presented with 6 months of worsening back pain with walking intolerance due to weakness in both legs. She had hypertension, asthma, and Cushing syndrome without bowel or bladder symptoms. Further workup demonstrated the presence of central spinal stenosis on magnetic resonance imaging. The patient underwent an L2-3 laminectomy and posterior decompression. Surgery was uneventful. RESULTS: The patient presented with acute abdominal distension, nausea, and vomiting on postoperative day 1. The patient was initially diagnosed with adynamic ileus and treated conservatively with bowel rest, reduction in narcotic dosage, and a regimen of stool softeners, laxatives, and enemas. Despite this treatment, her clinical course failed to improve, and she demonstrated significant colonic distension radiographically. Intravenous neostigmine was administered as a bolus with a rapid and dramatic response. CONCLUSION: Ogilvie's syndrome should be included in the differential diagnosis of postoperative ileus in patients developing prolonged unexplained abdominal distension and pain after lumbar spinal surgery. Early diagnosis and initiation of conservative management can prevent major morbidity and mortality due to bowel ischemia and perforation.
Aged, 80 and over
;
Asthma
;
Back Pain
;
Colon
;
Colonic Pseudo-Obstruction
;
Cushing Syndrome
;
Decompression
;
Diagnosis
;
Diagnosis, Differential
;
Early Diagnosis
;
Enema
;
Female
;
Humans
;
Hypertension
;
Ileus
;
Ischemia
;
Laminectomy
;
Laxatives
;
Leg
;
Magnetic Resonance Imaging
;
Mortality
;
Nausea
;
Neostigmine
;
Spinal Stenosis
;
Urinary Bladder
;
Vomiting
;
Walking
7.Role of DNA Methylation in the Development and Differentiation of Intestinal Epithelial Cells and Smooth Muscle Cells
Brian G JORGENSEN ; Seungil RO
Journal of Neurogastroenterology and Motility 2019;25(3):377-386
The mammalian intestine contains many different cell types but is comprised of 2 main cell types: epithelial cells and smooth muscle cells. Recent in vivo and in vitro evidence has revealed that various alterations to the DNA methylation apparatus within both of these cell types can result in a variety of cellular phenotypes including modified differentiation status, apoptosis, and uncontrolled growth. Methyl groups added to cytosines in regulatory genomic regions typically act to repress associated gene transcription. Aberrant DNA methylation patterns are often found in cells with abnormal growth/differentiation patterns, including those cells involved in burdensome intestinal pathologies including inflammatory bowel diseases and intestinal pseudo-obstructions. The altered methylation patterns being observed in various cell cultures and DNA methyltransferase knockout models indicate an influential connection between DNA methylation and gastrointestinal cells' development and their response to environmental signaling. As these modified DNA methylation levels are found in a number of pathological gastrointestinal conditions, further investigations into uncovering the causative nature, and controlled regulation, of this epigenetic modification is of great interest.
Apoptosis
;
Cell Culture Techniques
;
Cell Differentiation
;
DNA Methylation
;
DNA
;
Epigenomics
;
Epithelial Cells
;
In Vitro Techniques
;
Inflammatory Bowel Diseases
;
Intestinal Mucosa
;
Intestinal Pseudo-Obstruction
;
Intestines
;
Methylation
;
Muscle, Smooth
;
Myocytes, Smooth Muscle
;
Pathology
;
Phenotype
8.Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review
Giovanni DI NARDO ; Federica VISCOGLIOSI ; Francesco ESPOSITO ; Vincenzo STANGHELLINI ; Maria Pia VILLA ; Pasquale PARISI ; Alessia MORLANDO ; Girolamo CALÒ ; Roberto DE GIORGIO
Journal of Neurogastroenterology and Motility 2019;25(4):508-514
Pediatric chronic intestinal pseudo-obstruction is a rare disorder characterized by a severe impairment of gastrointestinal motility leading to intestinal obstruction symptoms in the absence of mechanical causes. The diagnosis is usually clinical and diagnostic work is usually aimed to rule out mechanical obstruction and to identify any underlying diseases. Treatment is challenging and requires a multidisciplinary effort. In this manuscript we describe the youngest child successfully treated with the orally administrable, long-acting, reversible anti-cholinesterase drug, pyridostigmine. Like other drugs belonging to cholinesterase inhibitors, pyridostigmine enhances gut motility by increasing acetylcholine availability in the enteric nervous system and neuro-muscular junctions. Based on the direct evidence from the reported case, we reviewed the current literature on the use of pyridostigmine in severe pediatric dysmotility focusing on intestinal pseudo-obstruction. The overall data emerged from the few published studies suggest that pyridostigmine is an effective and usually well tolerated therapeutic options for patients with intestinal pseudo-obstruction. More specifically, the main results obtained by pyridostigmine included marked reduction of abdominal distension, reduced need of parenteral nutrition, and improvement of oral feeding. The present case and review on pyridostigmine pave the way for eagerly awaited future randomized controlled studies testing the efficacy of cholinesterase inhibitors in pediatric severe gut dysmotility.
Acetylcholine
;
Child
;
Cholinesterase Inhibitors
;
Diagnosis
;
Enteric Nervous System
;
Female
;
Gastrointestinal Motility
;
Humans
;
Intestinal Obstruction
;
Intestinal Pseudo-Obstruction
;
Parenteral Nutrition
;
Pyridostigmine Bromide
9.Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report.
Shun Ting CHIANG ; Chen Chia LAN
Clinical Psychopharmacology and Neuroscience 2018;16(2):228-231
The mechanism of medication-induced gastrointestinal hypomotility is primarily caused by muscarinic cholinergic antagonism. This effect may cause constipation and paralytic ileus, which may lead to fatal complications. A 51-year-old woman was admitted due to manic episode recurrence. She developed paralytic ileus under quetiapine use and treated successfully under low dose amisulpride use. The related mechanism, associated risk factors, and the rationale for medication switch are discussed.
Bipolar Disorder
;
Cholinergic Antagonists
;
Constipation
;
Female
;
Humans
;
Intestinal Pseudo-Obstruction*
;
Middle Aged
;
Quetiapine Fumarate*
;
Recurrence
;
Risk Factors
10.Serial Frozen Fecal Microbiota Transplantation in the Treatment of Chronic Intestinal Pseudo-obstruction: A Preliminary Study.
Lili GU ; Chao DING ; Hongliang TIAN ; Bo YANG ; Xuelei ZHANG ; Yue HUA ; Yifan ZHU ; Jianfeng GONG ; Weiming ZHU ; Jieshou LI ; Ning LI
Journal of Neurogastroenterology and Motility 2017;23(2):289-297
BACKGROUND/AIMS: Chronic intestinal pseudo-obstruction (CIPO) is a serious, life-threatening motility disorder that is often related to bacterial overgrowth. Fecal microbiota transplantation (FMT) results in restoration of the normal intestinal microbial community structure. We investigated the efficacy of FMT in the treatment of CIPO patients. METHODS: Nine patients (age 18–53 years) with CIPO were enrolled in this prospective, open-label study. Patients received FMT for 6 consecutive days through nasojejunal (NJ) tubes and were followed up for 8 weeks after treatment. We evaluated the rate of clinical improvement and remission, feeding tolerance of enteral nutrition, and CT imaging scores of intestinal obstructions. Lactulose hydrogen breath tests were performed before FMT and 8 weeks after FMT to evaluate for the presence small intestinal bacterial overgrowth (SIBO). RESULTS: FMT significantly alleviated bloating symptoms, and symptoms of pain were relieved 2 weeks after FMT. Enteral nutrition administered through a NJ tube after FMT was well-tolerated by 66.7% (6/9) of patients. CT scores of intestinal obstructions were significantly reduced after FMT (P = 0.014). SIBO was eliminated in 71.0% (5/7) of patients. CONCLUSIONS: This pilot study demonstrated the safety of using FMT. FMT may relieve symptoms in selected patients with CIPO. FMT may also improve patient tolerance of enteral nutrition delivered via a NJ tube.
Breath Tests
;
Enteral Nutrition
;
Fecal Microbiota Transplantation*
;
Humans
;
Hydrogen
;
Intestinal Obstruction
;
Intestinal Pseudo-Obstruction*
;
Lactulose
;
Pilot Projects
;
Prospective Studies

Result Analysis
Print
Save
E-mail